骨髓增殖性肿瘤患者JAK2V617F突变与临床特征的关联性分析及其临床意义  

Correlation analysis on JAK2V617F mutation and clinical features in patients with myeloproliferative neoplasms and its clinical significance

作　　者：胡晓 於秋燕 徐文[1] 王春红[1] 金立方[1] 金鑫[1] 李小丰[1] 王秀丽[1] 于晓艳[2] 李景贺[1] HU Xiao;YU Qiuyan;XU Wen;WANG Chunhong;JIN Lifang;JIN Xin;LI Xiaofeng;WANG Xiuli;YU Xiaoyan;LI Jinghe(Department of Hematology and Oncology, Second Hospital,JilinUniversity, Changchun 130041,China;Department of Experimental Pharmacology and Toxicology,School of Pharmacy,Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第二医院肿瘤血液科,吉林长春130041 [2]吉林大学药学院实验药理与毒理学教研室,吉林长春130021

出　　处：《吉林大学学报（医学版）》2019年第5期1106-1112,共7页Journal of Jilin University：Medicine Edition

基　　金：吉林省科技厅科技发展计划项目资助课题(20180414026GH)

摘　　要：目的:研究JAK2V617F突变在骨髓增殖性肿瘤(MPN)患者中的分布情况,探讨JAK2V617F突变与MPN临床特征的关联性,阐明其在MPN患者诊疗过程中的临床意义。方法:选择170例MPN患者作为研究对象,将其分为真性红细胞增多症(PV)组(n=68)、原发性血小板增多症(ET)组(n=88)和原发性骨髓纤维化(PMF)组(n=14),采用等位基因特异性PCR(AS-PCR)法检测170例MPN患者JAK2V617F突变情况,分析各组内JAK2V617F突变型与野生型患者性别分布、年龄、白细胞计数、血红蛋白、血小板计数、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、D-二聚体水平、是否并发脾肿大和血栓栓塞方面的差别。结果:在170例MPN患者中JAK2V617F的总突变率为68.2%(116/170),PV、ET和PMF组的突变率分别为72.1%(49/68)、68.1%(60/88)和50.0%(7/14),PV组患者中的JAK2V617F突变率高于其他2组,但差异无统计学意义(P=0.281)。与野生型组比较,JAK2V617F突变型PV患者发病年龄、白细胞和血小板计数明显升高(P<0.01),PT和APTT明显延长(P<0.01),脾肿大发生率升高(P<0.05);JAK2V617F突变型ET患者白细胞计数升高(P<0.01),血红蛋白水平降低(P<0.01),APTT明显延长(P<0.01),血栓栓塞事件发生率升高(P<0.05);JAK2V617F突变型PMF患者发病年龄增加(P<0.05),白细胞和血小板计数升高(P<0.05或P<0.01)。与JAK2V617F突变型ET和PMF患者比较,JAK2V617F突变型PV患者APTT明显延长(P<0.05);与JAK2V617F突变型PV和ET患者比较,JAK2V617F突变型PMF患者发病年龄增加及白细胞计数升高(P<0.05)。结论:JAK2V617F突变型MPN患者与野生型患者临床特征明显不同;JAK2V617F突变型MPN患者中PV、ET和PMF临床特征也不尽相同,JAK2V617F突变型PV患者更易发生APTT延长,JAK2V617F突变型PMF患者发病年龄更大且白细胞计数更高。Objective : To investigate the distribution of JAK2V617F mutation in the patients with myeloproliferative neoplasms (MPN), to explore the association between JAK2V617F mutation and the clinical features of MPN, and to clarify its clinical significance in the diagnosis and treatment of the MPN patients. Methods : A total of 170 patients with MPN were selected as the subjects and divided into true polycythemia (PV) group ( n =68), primary thrombocytopenia (ET) group ( n =88) and primary myelofibrosis (PMF) group ( n =14).The JAK2V617F mutations in 170 patients with MPN were detected by allele-specific PCR (AS-PCR). The differences in gender, age, white blood cell count, hemoglobin,platelet count, prothrombin time(PT),activated partial thromboplastin time(APTT), D-dimer, whether complicated with splenomegaly and thromboembolism of the JAK2V617F mutant-type and wild-type patients in each group were analyzed. Results : The total mutation rate of JAK2V617F mutation in 170 patients with MPN was 68.2%(116/170), and the mutation rates in PV, ET, and PMF groups were 72.1%(49/68), 68.1%(60/88), and 50.0%(7/14), respectively.The JAK2V617F mutation rate in PV group was higher than those in the other two groups, but there were no statistical differences( P =0.281). Compared with wild type group, the age of onset, the white blood cell and platelet counts of the PV patients with JAK2V617F mutation were significantly increased ( P <0.01), PT and APTT were significantly prolonged( P <0.01), and the incidence of sp lenomegaly was increased ( P <0.05);the white blood cell count of the the ET patients with JAK2V617F mutation was increased( P <0.01),the hemoglobin level was decreased ( P <0.01), APTT was significantly prolonged( P <0.01), and the incidence of thromboembolic events was increased ( P <0.05);the age of onset, the white blood cell and platelet counts of the PMF patients with JAK2V617F mutation were signficantly increased ( P <0.05 or P <0.01).Compared with the ET and PMF patients with JAK2V617F mutation, APTT in the PV pa

关 键 词：骨髓增殖性肿瘤 JAK2V617F 基因突变 白细胞计数 活化部分凝血活酶时间 血栓形成 

分 类 号：R733.3[医药卫生—肿瘤]